ID

35340

Beschreibung

Efficacy and Safety of Bendamustine Plus Rituximab in Chronic Lympocytic Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT02491398

Link

https://clinicaltrials.gov/show/NCT02491398

Stichworte

Versionen (1)
  1. 28.02.19 28.02.19 -
Rechteinhaber

See clinicaltrials.gov

Hochgeladen am

28. Februar 2019

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

  • Neueste
  • Älteste
  • Beliebt
  • Neueste
    • Neueste
    • Älteste
    • Beliebt

Keine Kommentare

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Chronic Lymphocytic Leukemia NCT02491398

Englisch

Eligibility Chronic Lymphocytic Leukemia NCT02491398

1 Formulare  
Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
diagnosis of cll / small lymphocytic lymphoma (cll/) according to the world health organisation (who) classification 2008.
Beschreibung

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Datentyp

boolean

Alias
UMLS CUI [1]
C1302547
patients who were treated with first and second-line bendamustine plus rituximab (br) from january 2008 to december 2014 from european centres adhering to the gimema group and the eric group.
Beschreibung

Bendamustine/rituximab First line treatment | Bendamustine/rituximab Second line treatment

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1328232
UMLS CUI [1,2]
C1708063
UMLS CUI [2,1]
C1328232
UMLS CUI [2,2]
C1710038
previously untreated cll patients requiring therapy according to the nci criteria (hallek m et al, blood 2008 - appendix g) and treated with at least one cycle of br as first-line treatment.
Beschreibung

Prior Therapy Absent | Chronic Lymphocytic Leukemia Treatment required for | bendamustine/rituximab Course Quantity

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1514463
UMLS CUI [1,2]
C0332197
UMLS CUI [2,1]
C0023434
UMLS CUI [2,2]
C0332121
UMLS CUI [3,1]
C1328232
UMLS CUI [3,2]
C0750729
UMLS CUI [3,3]
C1265611
cll patients that received one previous line of treatment using alkylating agents and/or purine analogues with or without monoclonal antibodies, requiring second-line therapy according to the nci criteria (hallek m et al, blood 2008 - appendix g) and treated with at least one cycle of bendamustine and rituximab.
Beschreibung

Prior Therapy Chronic Lymphocytic Leukemia | Alkylating Agents | Purine analog | Monoclonal Antibodies | Monoclonal Antibodies Absent | Patient need for Second line treatment | bendamustine/rituximab Course Quantity

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1514463
UMLS CUI [1,2]
C0023434
UMLS CUI [2]
C0002073
UMLS CUI [3]
C1268902
UMLS CUI [4]
C0003250
UMLS CUI [5,1]
C0003250
UMLS CUI [5,2]
C0332197
UMLS CUI [6,1]
C0686904
UMLS CUI [6,2]
C1710038
UMLS CUI [7,1]
C1328232
UMLS CUI [7,2]
C0750729
UMLS CUI [7,3]
C1265611
age ≥ 18 years old.
Beschreibung

Age

Datentyp

boolean

Alias
UMLS CUI [1]
C0001779
signed written informed consent according to ich/eu/gcp and national local law.
Beschreibung

Informed Consent

Datentyp

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients who have received 2 or more lines of prior therapy.
Beschreibung

Prior Therapy Quantity

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1514463
UMLS CUI [1,2]
C1265611
patients with:
Beschreibung

Patients Have

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0030705
UMLS CUI [1,2]
C3539897
transformation of cll into aggressive lymphomas (richter's syndrome). hiv infection. active and uncontrolled hcv and/or hbv infections or liver cirrhosis.
Beschreibung

Chronic lymphocytic leukaemia transformation Aggressive Lymphoma | Richter's syndrome | HIV Infection | Hepatitis C Uncontrolled | Hepatitis B Uncontrolled | Liver Cirrhosis Uncontrolled

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1142081
UMLS CUI [1,2]
C1332225
UMLS CUI [2]
C0349631
UMLS CUI [3]
C0019693
UMLS CUI [4,1]
C0019196
UMLS CUI [4,2]
C0205318
UMLS CUI [5,1]
C0019163
UMLS CUI [5,2]
C0205318
UMLS CUI [6,1]
C0023890
UMLS CUI [6,2]
C0205318
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Eligibility Chronic Lymphocytic Leukemia NCT02491398

1 Formulare
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Item
diagnosis of cll / small lymphocytic lymphoma (cll/) according to the world health organisation (who) classification 2008.
boolean
C1302547 (UMLS CUI [1])
Bendamustine/rituximab First line treatment | Bendamustine/rituximab Second line treatment
Item
patients who were treated with first and second-line bendamustine plus rituximab (br) from january 2008 to december 2014 from european centres adhering to the gimema group and the eric group.
boolean
C1328232 (UMLS CUI [1,1])
C1708063 (UMLS CUI [1,2])
C1328232 (UMLS CUI [2,1])
C1710038 (UMLS CUI [2,2])
Prior Therapy Absent | Chronic Lymphocytic Leukemia Treatment required for | bendamustine/rituximab Course Quantity
Item
previously untreated cll patients requiring therapy according to the nci criteria (hallek m et al, blood 2008 - appendix g) and treated with at least one cycle of br as first-line treatment.
boolean
C1514463 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0023434 (UMLS CUI [2,1])
C0332121 (UMLS CUI [2,2])
C1328232 (UMLS CUI [3,1])
C0750729 (UMLS CUI [3,2])
C1265611 (UMLS CUI [3,3])
Prior Therapy Chronic Lymphocytic Leukemia | Alkylating Agents | Purine analog | Monoclonal Antibodies | Monoclonal Antibodies Absent | Patient need for Second line treatment | bendamustine/rituximab Course Quantity
Item
cll patients that received one previous line of treatment using alkylating agents and/or purine analogues with or without monoclonal antibodies, requiring second-line therapy according to the nci criteria (hallek m et al, blood 2008 - appendix g) and treated with at least one cycle of bendamustine and rituximab.
boolean
C1514463 (UMLS CUI [1,1])
C0023434 (UMLS CUI [1,2])
C0002073 (UMLS CUI [2])
C1268902 (UMLS CUI [3])
C0003250 (UMLS CUI [4])
C0003250 (UMLS CUI [5,1])
C0332197 (UMLS CUI [5,2])
C0686904 (UMLS CUI [6,1])
C1710038 (UMLS CUI [6,2])
C1328232 (UMLS CUI [7,1])
C0750729 (UMLS CUI [7,2])
C1265611 (UMLS CUI [7,3])
Age
Item
age ≥ 18 years old.
boolean
C0001779 (UMLS CUI [1])
Informed Consent
Item
signed written informed consent according to ich/eu/gcp and national local law.
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Prior Therapy Quantity
Item
patients who have received 2 or more lines of prior therapy.
boolean
C1514463 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
Patients Have
Item
patients with:
boolean
C0030705 (UMLS CUI [1,1])
C3539897 (UMLS CUI [1,2])
Chronic lymphocytic leukaemia transformation Aggressive Lymphoma | Richter's syndrome | HIV Infection | Hepatitis C Uncontrolled | Hepatitis B Uncontrolled | Liver Cirrhosis Uncontrolled
Item
transformation of cll into aggressive lymphomas (richter's syndrome). hiv infection. active and uncontrolled hcv and/or hbv infections or liver cirrhosis.
boolean
C1142081 (UMLS CUI [1,1])
C1332225 (UMLS CUI [1,2])
C0349631 (UMLS CUI [2])
C0019693 (UMLS CUI [3])
C0019196 (UMLS CUI [4,1])
C0205318 (UMLS CUI [4,2])
C0019163 (UMLS CUI [5,1])
C0205318 (UMLS CUI [5,2])
C0023890 (UMLS CUI [6,1])
C0205318 (UMLS CUI [6,2])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video